trending Market Intelligence /marketintelligence/en/news-insights/trending/grt64r4tytFRin8mfW0eSQ2 content esgSubNav
In This List

Lilly's Emgality wins US FDA nod as 1st therapy for episodic cluster headaches

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022

Blog

Insight Weekly: Challenges for European banks; Japan's IPO slowdown; carmakers' supply woes

Blog

Investment Banking Essentials Newsletter April Edition - 2022


Lilly's Emgality wins US FDA nod as 1st therapy for episodic cluster headaches

The U.S. Food and Drug Administration approved Eli Lilly and Co.'s Emgality as the first drug for treating episodic cluster headaches in adults.

Cluster headaches are recurrent attacks of severe headaches on one side of the head, frequently associated with pain behind or around one eye, restlessness and agitation. The attacks typically last 15 to 180 minutes and can occur many times a day during a cluster period.

Emgality, or galcanezumab, is an under-the-skin injection that can be self-administered once a month.

The FDA's approval for Emgality is based on a phase 3 study, which showed that the drug helped reduce weekly episodes of cluster headaches.

Emgality is already approved for preventing migraine in adults. The U.S. FDA granted a breakthrough-therapy designation to Emgality in September 2018 and a priority review status in March 2019.